J&J raises FY26 outlook following positive Q2

EarningsShockwave IVL systemPositive

AI Analysis

Summary

Johnson & Johnson raised its FY26 outlook following positive Q2 results, with MedTech contributing $8.9bn in revenues driven by its cardiovascular portfolio including the Shockwave IVL system.

Financial Highlights

Revenue

$25.3bn (Q2 total); $8.9bn (MedTech)

Guidance

FY26 outlook raised

Importance:5/10

Sentiment:

0.70

earningsguidance_raisemedtechcardiovascularrevenue_growth

Related Companies

$JNJ

Read the original article

Published by Pharmaceutical Technology on July 15, 2026 2:14 PM

Read Original